Hepatitis A Virus PRevalence, Educational assessment for Vaccination, Evaluation of Natural immunity and Treatment.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Incidence of complications (ALF, ACLF)
研究概览
简要总结
The HAV-PREVENT study is a mixed-methods observational study aimed at understanding the epidemiology of Hepatitis A virus infections and vaccination attitudes in North India. The study comprises three components: (1) a retrospective analysis of HAV cases over 3 years to characterize clinical outcomes and complications, (2) a cross-sectional seroprevalence survey of HAV antibodies in patients with cirrhosis, and (3) an assessment of knowledge, attitudes, and practices regarding HAV vaccination with a brief educational intervention. The study aims to identify risk factors for severe complications, evaluate the burden of HAV-related hospitalizations, and develop targeted prevention strategies. Results will inform vaccination policies and public health interventions for HAV prevention in high-risk populations.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •Retrospective Component: All patients (age greater than equal to 18 years) with positive HAV IgM test results from Jan 1, 2022, to Dec 31, 2024 Prospective Component: All consenting adults (age greater than equal to 18 years) with cirrhosis admitted in Gastroenterology Department between 1 July 2025, and September 30 2025 Patients with negative or unknown HAV vaccination status.
排除标准
- •Age less than 18 years Pregnant women Inability to provide informed consent (for seroprevalence and attitudes components) Previous documented HAV vaccination (for attitudes and intervention component only).
结局指标
主要结局
Incidence of complications (ALF, ACLF)
次要结局
- Overall mortality and cause-specific mortality
研究者
DrRamit Mahajan
Dayanand Medical College and Hospital